This study has three aims that hope to expand the knowledge on the cause of Sturge-Weber Syndrome (SWS) and improve clinical care of Sturge-Weber Syndrome patients.
This study is one of three projects of an NIH Rare Disease Clinical Research Consortium focused on brain blood vessel malformations in three different rare diseases. The focus of this project is on Sturge-Weber Syndrome.
We plan to improve the future understanding and treatment of Sturge-Weber Syndrome by 1) establishing a national consortium database which will gather lager amounts of clinical data and serve indirectly as a registry to foster future clinical trials and determine the usefulness of urine vascular biomarkers to determine the vascular remodeling of the SWS birthmark and choroidal angioma, 2) study vascular remodeling with retrospective and prospective neuroimaging to determine the vascular remodeling of the deep draining intraparenchymal vessels as it relates to SWS neurologic status, and 3) relate the GNAQ mutation to altered phosphorylation of pathway proteins and angiogenesis factors in SWS tissue.
- Perspective: Cross-Sectional
- Sampling: Non-Probability Sample
For Aim 1, the population will be subjects with Sturge-Weber Syndrome and diagnosed brain involvement. There will be a separate group made up of family members of those with Sturge-Weber syndrome brain involvement to have as a control for the urine portion of Aim 1. For the optical coherence tomography (OCT) portion of Aim 1, the population will be subjects with Sturge-Weber Syndrome eye involvement. For Aim 2, the population will be subjects that have Sturge-Weber Syndrome with brain involvement. For Aim 3, the population will be subjects with Sturge-Weber Syndrome, diagnosed brain involvement, and V1 distribution Port-Wine Stain.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Aim 1||All 5 years||No|
|Primary||Aim 2||Years 1-3||No|
|Primary||Aim 3||Years 1-4||No|
Biospecimen Retention:Samples With DNA - Aim 1 retains data and samples without DNA. Aim 2 retains data without DNA. Aim 3 retains anonymous data with DNA.
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc. Lead
- National Institutes of Health (NIH)
- New York University
- Texas Children's Hospital
- Nationwide Children's Hospital
- Baylor College of Medicine
- University of California, San Francisco
- National Institute of Neurological Disorders and Stroke (NINDS)
- Wills Eye
- Children's Hospital of Michigan
- Children's Hospital Medical Center, Cincinnati
- Duke University